Table 3. Selected adverse events of gemcitabine/erlotinib treatment for advanced pancreatic cancer.
| Type | No. of studies | Grade½ (%, n/N) | Grade¾ (%, n/N) | Total (%, n/N) |
| All together | 3 | – | 62.9% (194/308) | 96.3% (419/435) |
| Treatment-related deaths | 4 | – | – | 2.1% (12/559) |
| Hematologic | ||||
| Anaemia | 7 | 29.1% (164/563) | 9.2% (62/671) | 30.6% (156/509) |
| Leukocytopenia | 4 | 60.9% (131/215) | 18.6% (40/215) | 71.2% (109/153) |
| Neutropenia | 8 | 14.8% (94/635) | 20.2% (150/743) | 32.9% (209/635) |
| Thrombocytopenia | 9 | 30.3% (204/673) | 7.3% (57/781) | 32.4% (206/635) |
| Gastrointestinal/hepatobiliary | ||||
| Anorexia | 3 | 28.2% (154/546) | 4.8% (26/546) | 33.0% (180/546) |
| Diarrhea | 11 | 44.8% (460/1026) | 5.6% (59/1052) | 47.0% (470/999) |
| Gastrointestinal perforations | 1 | 0% (0/287) | 1.4% (4/287) | 1.4% (4/287) |
| Nausea | 4 | 54.2% (247/456) | 4.1% (20/482) | 51.4% (202/393) |
| Stomatitis | 5 | 26.5% (155/584) | 1.2% (7/584) | 24.8% (139/561) |
| Vomiting | 4 | 37.5% (152/405) | 4.0% (16/405) | 35.8% (132/369) |
| Dermatologic | ||||
| Rash | 11 | 40.5% (420/1038) | 18.9% (208/1100) | 57.9% (586/1012) |
| Other | ||||
| Asthenia/Fatigue | 5 | 30.2% (232/768) | 3.5% (27/768) | 33.7% (259/768) |
| Fever | 4 | 27.9% (160/573) | 1.0% (6/573) | 29.0% (166/573) |
| Hemarrhage | 1 | 17.8% (51/287) | 5.6% (16/287) | 23.3% (67/287) |
| Infection | 3 | 27.3% (105/385) | 19.5% (75/385) | 40.4% (139/344) |
| ILD-like syndrome | 1 | – | – | 2.5% (7/282) |
N, total number of patients; ILD, interstitial lung disease.